TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06764940: A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients With Brain Metastases

Sponsor: Biostar Pharma, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$11,688,600

Rescue Site Savings

+$7,715,400

Unlock Full NCT06764940 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06764940 Rescue Dossier →